Follicular lymphoma

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, May 12, 2023
CLL, Waldenström macroglobulinemia, Mayo Clinic, Arm, Chronic lymphocytic leukemia, Follicular lymphoma, Fred Hutchinson Cancer Research Center, ICML, Clinical trial, Lymphoma, Security agreement, Research, Runway, Translation, WM, Waldenström, CAR, Hematological Cancer Research Investment and Education Act, International Conference on Afghanistan, London (2010), Patient, Clinical professor, FDA, Loan, Mustang, Conference, DSM-IV codes, Safety, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.
  • The final dose level escalation is anticipated in the Phase 1 indolent lymphoma arm in the third quarter of this year.
  • Research and development expenses were $14.0 million for the first quarter of 2023, compared to $16.3 million for the first quarter of 2022.
  • General and administrative expenses were $2.3 million for the first quarter of 2023, compared to $3.3 million for the first quarter of 2022.

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Retrieved on: 
Thursday, May 11, 2023
University, European Hematology Association, Chronic lymphocytic leukemia, Follicular lymphoma, Fred Hutchinson Cancer Research Center, DSM-IV codes, University of Washington, Lymphoma, Associate, Translation, CAR, Hematological Cancer Research Investment and Education Act, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Mustang, Conference, Safety, Pharmaceutical industry

WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”), will be presented at the European Hematology Association (“EHA2023”) Hybrid Congress taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma (“ICML”) taking place June 13-17, 2023, in Lugano, Switzerland.

Key Points: 
  • Both presentations will be given by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutchinson Cancer Center (“Fred Hutch”) and University of Washington.
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutch.
  • “As we continue to progress our CD20-targeted CAR T cell therapy program, we look forward to the upcoming presentations highlighting data from the Phase 1/2 study of MB-106 taking place at Fred Hutch.
  • “Looking ahead, Mustang plans to provide a data update in the near future from our Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 in a multicenter setting.”
    Details of the presentations are as follows:

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, May 11, 2023
Topotecan, GLP, Carcinoma, Abstract, Rituximab, LSD1, AACR, Cancer prevention, Follicular lymphoma, DLBCL, European Hematology Association, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Biotechnology, Clinical trial, Lenalidomide, NHL, CD20, American Association for Cancer Research, Cyclophosphamide, Salinicola salarius, SCLC, Bortezomib, Congress, Investigational New Drug, Hematological Cancer Research Investment and Education Act, Patient, Toxicology, Neoplasm, Ewing sarcoma, Research institute, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, News, Food, Cancer Prevention and Research Institute of Texas, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Video game

HOUSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $9.3 million as of March 31, 2023, compared with $12.1 million as of December 31, 2022.
  • The decline reflects lower spending on seclidemstat in the 2023 quarter and one-time expenses of $2.0 million related to the purchase of the targeted protein degrader program in the 2022 quarter.
  • “In addition, Salarius continued to execute on plan during the first quarter of 2023 and recent weeks as we advanced the development of SP-3164, our targeted protein degrader.
  • Salarius will be participating in the 2023 BIO International Convention in Boston June 5-8, and the European Hematology Association 2023 Congress in Frankfurt, Germany June 8-11.

The Mark Foundation for Cancer Research Appoints Two New Members to Board of Directors

Retrieved on: 
Wednesday, May 10, 2023
Advertising, Korn Ferry, Follicular lymphoma, Meta, Workplace, Picturehouse (band), World Cancer Day, Cancer, DKFZ, Research, German Cancer Aid, German Cancer Research Center, Doctor of Philosophy, Nicola, BBH, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Othmar, National Executive Board of the Boy Scouts of America, Science, Patient, Helmholtz Association, Memorial Sloan Kettering Cancer Center, Diagnosis, Mendelssohn (surname), Pharmaceutical industry, Management, Diageo, MD

NEW YORK, May 10, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced today the appointment of two new members to its Board of Directors. Nicola Mendelsohn CBE, Head of Global Business at Meta, and Otmar Wiestler, MD, President of the Helmholtz Association, Germany's largest scientific organization, were elected at The Mark Foundation's April board meeting. Their terms are effective immediately. Both new board members are well-positioned and uniquely qualified to support the Foundation's mission of accelerating research that will transform the prevention, diagnosis, and treatment of cancer.

Key Points: 
  • Nicola Mendelsohn CBE, Head of Global Business Group at Meta, and Otmar Wiestler, President of Helmholtz Association, join board of global leader in cancer research funding
    NEW YORK, May 10, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced today the appointment of two new members to its Board of Directors.
  • Both new board members are well-positioned and uniquely qualified to support the Foundation's mission of accelerating research that will transform the prevention, diagnosis, and treatment of cancer.
  • "We are honored to welcome these distinguished members to The Mark Foundation Board of Directors," said Ray DuBois, MD, PhD, Executive Chairman.
  • "The Mark Foundation is committed to accelerating cancer research on a global scale; since 2017 they have funded outstanding grantees in 13 countries," said Otmar Wiestler.

BostonGene and Australia’s Mater Research Collaborate in New Follicular Lymphoma Study

Retrieved on: 
Tuesday, May 2, 2023
Oncology, Health, Genetics, Research, Science, Biotechnology, ASH, Follicular lymphoma, RNA-Seq, Survival, Bone marrow, Multimedia, Biomarker, RNA, Hospital, MD, Patient, Physician, Neoplasm, Society, Biopsy, Disease, Pharmaceutical industry, Medical imaging, Vaccine

BostonGene Corporation has announced a major research collaboration with Australia’s Mater Research to discover novel diagnostic biomarkers of follicular lymphoma and ultimately improve treatment for patients in the advanced stages of the disease.

Key Points: 
  • BostonGene Corporation has announced a major research collaboration with Australia’s Mater Research to discover novel diagnostic biomarkers of follicular lymphoma and ultimately improve treatment for patients in the advanced stages of the disease.
  • View the full release here: https://www.businesswire.com/news/home/20230502005055/en/
    Follicular lymphoma is a type of blood cancer diagnosed in around 1,500 Australians yearly and is usually slow-growing.
  • Led by Honorary Senior Research Fellow Dr Joshua Tobin, Mater Research will work with US-based molecular and immune profiling leader BostonGene to analyze hundreds of follicular lymphoma (FL) biopsy samples and assess the prognostic impact of changes in immune function within each tumor.
  • “We are pleased to support Mater Research in its research efforts to find optimal treatments for Mater, and ultimately all, patients with follicular lymphoma,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Cellular Biomedicine Group Announces Exclusive Collaboration and License Agreement with Janssen to Develop and Commercialize anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma

Retrieved on: 
Tuesday, May 2, 2023
Biologics license application, CD20, DLBCL, NHL, Cancer, Hope, Janssen, Follicular lymphoma, Orphan drug, Non-Hodgkin lymphoma, Patient, FDA, BLA, IND, Technology transfer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry

The U.S. Food and Drug Administration (FDA) has granted C-CAR039 Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designation for relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL).

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has granted C-CAR039 Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designation for relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL).
  • Furthermore, C-CAR039 has also received Orphan Drug designation from the FDA for the treatment of Follicular lymphoma (FL).
  • "We are very excited to announce the C-CAR039 and C-CAR066 CAR-T collaboration and license agreement with Janssen to develop and commercialize our novel CAR-T therapies," said Tony (Bizuo) Liu, Chairman and CEO of CBMG.
  • We feel privileged to work with Janssen to advance the promise of our innovative medicines."

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

Retrieved on: 
Wednesday, April 26, 2023
Cayman, CD19, Marketing, Breakthrough therapy, Patient, Immunoglobulin G, National Medical Products Administration, MM, Bone marrow, Therapy, Multiple myeloma, CASI Pharmaceuticals, FDA, IND, NMPA, Safety, ALL, ODD, CASI, Non-Hodgkin lymphoma, COVID-19, Acute lymphoblastic leukemia, Haematopoietic system, Acute myeloid leukemia, B-ALL, Annual report, Research, Pembrolizumab, VCP, Myelodysplastic syndrome, Rituximab, Follicular lymphoma, Center for Drug Evaluation and Research, NDA, NHL, CTA, MDS, AML, Clinical trial, City, MCL, Transplant, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, Juventas

BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022.

Key Points: 
  • BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022.
  • Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $10.2 million in EVOMELA® revenues for the fourth quarter, $38 million for the full-year 2022.
  • 2022 marks a major milestone for CASI and our partner Juventas; the CNCT-19 New Drug Application (NDA) was accepted by National Medical Products Administration (NMPA) in December 2022.
  • As of December 31, 2022, CASI had cash and cash equivalents of $47.1 million compared to $38.7 million as of December 31, 2021.

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, April 20, 2023
Immortalised cell line, Abstract, AACR, Follicular lymphoma, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Lenalidomide, NHL, American Association for Cancer Research, Bortezomib, Patient, Apoptosis, Poster, Pharmaceutical industry, Vaccine, Salinicola salarius

HOUSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced the presentation of two posters related to the company’s novel molecular glue, SP-3164, at the American Association for Cancer Research (AACR) Annual Meeting. Both abstracts highlight preclinical findings with SP-3164, with one focused on non-Hodgkin lymphoma (NHL) and the other on multiple myeloma (MM).

Key Points: 
  • Both abstracts highlight preclinical findings with SP-3164, with one focused on non-Hodgkin lymphoma (NHL) and the other on multiple myeloma (MM).
  • “These two studies presented at the prestigious AACR Annual Meeting are adding to the growing body of SP-3164 preclinical data demonstrating anticancer activity alone and in combination with standard-of-care treatments,” said David Arthur, president and chief executive officer of Salarius.
  • In addition, the data showed SP-3164 induced apoptosis in multiple myeloma cell lines.
  • In animal models, SP-3164 demonstrated superior single-agent activity compared to both lenalidomide (Revlimid®) and pomalidomide (Pomalyst®).

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
CLL, Lymphoma, AACR, ASH, Therapy, KSP, Doctor of Philosophy, Chronic lymphocytic leukemia, Follicular lymphoma, Lymphoid leukemia, DLBCL, Neoplasm, PALO, Survival, Cancer, Toxicity, Antibody, B-cell lymphoma, PDX, Plasma, Patient, Mantle cell lymphoma, CXCR5, Mouse, Immunohistochemistry, ADC, MCL, Poster, IND, Human, Safety, Pharmaceutical industry, Vaccine, Medical imaging

PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • This modification allows for intracellular accumulation of VIP716 in CXCR5+ tumor cells, providing greater efficacy, and prevents cellular penetration into healthy tissues, reducing toxicity.
  • “We are thrilled to continue advancing our bioconjugation platform with our newest ADC, VIP924,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx.
  • “At AACR, VIP924 showed meaningful preclinical activity in a panel of lymphoma cell lines and in cell line-derived and patient-derived lymphoma mouse models.

GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Health, Clinical Trials, Health Technology, Oncology, CLL, DNA, AACR, Methylation, Chronic lymphocytic leukemia, Follicular lymphoma, DLBCL, Multiple myeloma, Bone marrow, Cancer, American Association for Cancer Research, LOD, AstraZeneca, B-cell lymphoma, Acute myeloid leukemia, MRD, Plasma, Patient, Machine learning, Mantle cell lymphoma, Algorithm, Medical imaging, GRAIL

The study showed that GRAIL’s methylation technology had a cancer detection rate of 92% in patients with relapsed or refractory disease across six hematological malignancies.

Key Points: 
  • The study showed that GRAIL’s methylation technology had a cancer detection rate of 92% in patients with relapsed or refractory disease across six hematological malignancies.
  • The findings were reported during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, held April 14-19.
  • “Currently there is no standard method to detect residual cancer DNA in patients across multiple types of blood cancer.
  • Cancer was reproducibly detected in 89% (48 of 54) of cases where paired samples were taken prior to treatment, demonstrating high biological precision.